Drug intelligence / Profile preview

MIV-802

Development stage: Preclinical
Lead developer: Trek Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

**MIV-802** is a highly potent, pan-genotypic, nucleotide-based small molecule inhibitor of the Hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase, the viral enzyme essential for HCV genome replication. Developed initially by Medivir AB, it demonstrated superior preclinical antiviral activity against HCV genotype 3 compared to sofosbuvir, with potential for use in combination regimens with other direct-acting antivirals targeting complementary HCV proteins. Preclinical studies confirmed a favorable safety profile, supporting its advancement, though clinical development appears limited as of recent reports.

Other names: MIV-802MIV802MIV 802

Targets

NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)

Beyond the preview

Go deeper on MIV-802.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MIV-802.

Explore the full profile